Navigation Links
NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
Date:4/14/2009

produced in insect cells, formed three-dimensional structures that mimic the 1918 pandemic influenza virus but without the genetic material needed for replication. The mechanism of action by which this H1N1 VLP vaccine candidate provided broad cross-protection is under further study, but the scientists described preliminary evidence that antibody cross-reactivity between the HA and possibly NA proteins of the H1N1 and H5N1 influenza were important.

"Unlike other non-live influenza vaccines, the VLPs are uniquely positioned to stimulate immunity through multiple mechanisms," said Dr. Penny Heaton, Chief Medical Officer at Novavax. "First, they contain HA protein that is the same structure as the live virus, which may stimulate HA antibodies of several types that not only prevent the virus from attaching to cells but also prevent the virus from fusing with cells. Second, the VLPs contain NA which may stimulate production of antibody that prevents spread of the virus down the respiratory tract. Finally, the structure of the HA and NA proteins and the way in which they are embedded in lipids on the surface of the VLP may activate the innate immune system providing protection against both the H1N1 and H5N1 strains," said Dr. Heaton.

Although cross protection against influenza strains of the same hemagglutinin or HA type has been achieved through the use of vaccines with adjuvants (e.g., cross-protection against H5N1 A/Vietnam and A/Indonesia strains), protection against strains with different HA types, as shown in this study, has not been reported. Cross-protection against different HA types is highly desirable for pandemic influenza vaccine candidates because it is not possible to predict the strain that may be responsible for the next pandemic with today's technology. A broadly cross-protective vaccine would be ideal for stockpiling in that it could be administered during the first wave of the pandemic while waiting for manuf
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
2. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
3. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
4. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
5. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
6. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
7. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
8. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
9. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
10. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
11. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013  Insero Health, Inc., a company ... epilepsy and related neurological disorders, is today reporting top-line ... compound INS001 in patients with drug-resistant epilepsy.  The data ... Trials (AED) Xll meeting by Dr. Steven ... of Insero,s Scientific Advisory Board.  In this study, INS001 ...
(Date:5/17/2013)... IAC Industries wants to share with you ... needing to set up and furnish a research lab knowing ... within a year’s time. How does a company make choices ... temporary? What is efficient and cost-effective? , The solution ... Industries. The planners at DisperSol determined that the concept of ...
(Date:5/16/2013)... In late 2012, Dr. Sarah Hart, of Palm Clinic ... about Appearance Medicine . Although Dr. Hart regularly teaches ... to lecture in China, and quite a different experience it ... 12 and 7 million people respectively. Interest in cosmetic facial ... in time. As Dr. Hart passed through the Fuzhou airport ...
(Date:5/16/2013)... 2013  The registration deadline has been extended until ... 2013 National Conference, the premier conference for bioscience financial ... the Hilton San Diego Bayfront. "We ... and want to make sure as many people as ... Brandi Roberts , Chief Financial Officer of Mast ...
Breaking Biology Technology:Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4
... Oct. 31 Novo Nordisk (NYSE:,NVO), a global healthcare company, today ... 30, 2007. -- Novo Nordisk increased sales by 14% in ... kroner due to a significant negative currency development. ... Danish kroner). -- Sales of NovoSeven(R) increased ...
... Kinetics Study ... Data, ... OTC: MGIFF), a clinical-stage developer of drugs for infectious,diseases will present at ... the New York Palace Hotel in New York,NY on November 5-7, 2007. ...
... (Nasdaq: IDIX ) announced today that it will ... on Tuesday, November 6,2007 after the U.S. financial markets ... press release, Idenix,management will host a conference call at ... the company,s financial results for the third quarter,2007. ...
Cached Biology Technology:Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin 2MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 3
(Date:5/16/2013)... Access to Research Careers) Program has announced the ... 95th Annual Meeting in San Francisco, CA from ... promote the entry of students, postdoctorates and scientists ... basic science community and to encourage the participation ... Meeting. , Awards are given to poster/platform presenters ...
(Date:5/16/2013)... scientists have used ancient shorelines to predict the stability of ... a high shoreline from three million years ago, for example ... were thought to be evidence of a high sea level ... has led many scientists to think that if the world,s ... do just the same in our modern, progressively warming world. ...
(Date:5/16/2013)... cellular layer lining the body,s blood vessels, is ... in thickness, this super-tenuous structure routinely withstands blood ... create a unique and highly dynamic barrier that ... the body,s circulatory system. , It,s also extremely ... physically breached to enable immune cells to ...
Breaking Biology News(10 mins):World's biggest ice sheets likely more stable than previously believed 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... the Marine Biological,Laboratory (MBL) has published the ... supports her hypothesis that, when combined, the ... BCE--can act synergistically to alter a key ... previously studied the effects,of these pollutants individually, ...
... of fluorescence detection developed by researchers at Baylor College ... doors that would take DNA sequencing to the patient's ... a crime or a battlefield. , "We could eventually ... DNA" without manipulation now performed in the laboratory, said ...
... The crystallized form of a molecular machine that can ... paths for treating diseases such as some forms of ... Purdue University researchers froze one of these molecular machines, ... intron, at mid-point in its work cycle. When frozen, ...
Cached Biology News:Study identifies predictors of HIV drug resistance in patients beginning triple therapy 2Study identifies predictors of HIV drug resistance in patients beginning triple therapy 3Color-blind method opens new doors in DNA sequencing 2Color-blind method opens new doors in DNA sequencing 3Molecular machine may lead to new drugs to combat human diseases 2Molecular machine may lead to new drugs to combat human diseases 3
... glycoprotein. distributed in colon and rectum, ... lung and salivary gland tissues. ... and MUC2. Epitope: Tandem repeats ... MUC3 tandem repeat peptide Positive ...
... This immunoaffinity purified antibody detects an ... molecular mass of ErbB-2 phosphorylated at tyrosine ... product has been cross adsorbed against the ... detect the non-phosphorylated form of the protein. ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
...
Biology Products: